Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer : a phase 2 umbrella trial
© 2024. The Author(s)..
For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L)1 checkpoint inhibitors, alone or with platinum-doublet therapy. However, not all patients derive durable benefit and resistance to immune checkpoint blockade is common. Understanding mechanisms of resistance-which can include defects in DNA damage response and repair pathways, alterations or functional mutations in STK11/LKB1, alterations in antigen-presentation pathways, and immunosuppressive cellular subsets within the tumor microenvironment-and developing effective therapies to overcome them, remains an unmet need. Here the phase 2 umbrella HUDSON study evaluated rational combination regimens for advanced NSCLC following failure of anti-PD-(L)1-containing immunotherapy and platinum-doublet therapy. A total of 268 patients received durvalumab (anti-PD-L1 monoclonal antibody)-ceralasertib (ATR kinase inhibitor), durvalumab-olaparib (PARP inhibitor), durvalumab-danvatirsen (STAT3 antisense oligonucleotide) or durvalumab-oleclumab (anti-CD73 monoclonal antibody). Greatest clinical benefit was observed with durvalumab-ceralasertib; objective response rate (primary outcome) was 13.9% (11/79) versus 2.6% (5/189) with other regimens, pooled, median progression-free survival (secondary outcome) was 5.8 (80% confidence interval 4.6-7.4) versus 2.7 (1.8-2.8) months, and median overall survival (secondary outcome) was 17.4 (14.1-20.3) versus 9.4 (7.5-10.6) months. Benefit with durvalumab-ceralasertib was consistent across known immunotherapy-refractory subgroups. In ATM-altered patients hypothesized to harbor vulnerability to ATR inhibition, objective response rate was 26.1% (6/23) and median progression-free survival/median overall survival were 8.4/22.8 months. Durvalumab-ceralasertib safety/tolerability profile was manageable. Biomarker analyses suggested that anti-PD-L1/ATR inhibition induced immune changes that reinvigorated antitumor immunity. Durvalumab-ceralasertib is under further investigation in immunotherapy-refractory NSCLC.ClinicalTrials.gov identifier: NCT03334617.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Nature medicine - 30(2024), 3 vom: 13. März, Seite 716-729 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Besse, Benjamin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 27.03.2024 published: Print-Electronic ClinicalTrials.gov: NCT03334617 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41591-024-02808-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368412946 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368412946 | ||
| 003 | DE-627 | ||
| 005 | 20240327235809.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240214s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41591-024-02808-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1351.xml |
| 035 | |a (DE-627)NLM368412946 | ||
| 035 | |a (NLM)38351187 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Besse, Benjamin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer |b a phase 2 umbrella trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 27.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03334617 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L)1 checkpoint inhibitors, alone or with platinum-doublet therapy. However, not all patients derive durable benefit and resistance to immune checkpoint blockade is common. Understanding mechanisms of resistance-which can include defects in DNA damage response and repair pathways, alterations or functional mutations in STK11/LKB1, alterations in antigen-presentation pathways, and immunosuppressive cellular subsets within the tumor microenvironment-and developing effective therapies to overcome them, remains an unmet need. Here the phase 2 umbrella HUDSON study evaluated rational combination regimens for advanced NSCLC following failure of anti-PD-(L)1-containing immunotherapy and platinum-doublet therapy. A total of 268 patients received durvalumab (anti-PD-L1 monoclonal antibody)-ceralasertib (ATR kinase inhibitor), durvalumab-olaparib (PARP inhibitor), durvalumab-danvatirsen (STAT3 antisense oligonucleotide) or durvalumab-oleclumab (anti-CD73 monoclonal antibody). Greatest clinical benefit was observed with durvalumab-ceralasertib; objective response rate (primary outcome) was 13.9% (11/79) versus 2.6% (5/189) with other regimens, pooled, median progression-free survival (secondary outcome) was 5.8 (80% confidence interval 4.6-7.4) versus 2.7 (1.8-2.8) months, and median overall survival (secondary outcome) was 17.4 (14.1-20.3) versus 9.4 (7.5-10.6) months. Benefit with durvalumab-ceralasertib was consistent across known immunotherapy-refractory subgroups. In ATM-altered patients hypothesized to harbor vulnerability to ATR inhibition, objective response rate was 26.1% (6/23) and median progression-free survival/median overall survival were 8.4/22.8 months. Durvalumab-ceralasertib safety/tolerability profile was manageable. Biomarker analyses suggested that anti-PD-L1/ATR inhibition induced immune changes that reinvigorated antitumor immunity. Durvalumab-ceralasertib is under further investigation in immunotherapy-refractory NSCLC.ClinicalTrials.gov identifier: NCT03334617 | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a durvalumab |2 NLM | |
| 650 | 7 | |a 28X28X9OKV |2 NLM | |
| 650 | 7 | |a ceralasertib |2 NLM | |
| 650 | 7 | |a 85RE35306Z |2 NLM | |
| 650 | 7 | |a Platinum |2 NLM | |
| 650 | 7 | |a 49DFR088MY |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a Indoles |2 NLM | |
| 650 | 7 | |a Morpholines |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 700 | 1 | |a Pons-Tostivint, Elvire |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Keunchil |e verfasserin |4 aut | |
| 700 | 1 | |a Hartl, Sylvia |e verfasserin |4 aut | |
| 700 | 1 | |a Forde, Patrick M |e verfasserin |4 aut | |
| 700 | 1 | |a Hochmair, Maximilian J |e verfasserin |4 aut | |
| 700 | 1 | |a Awad, Mark M |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Goss, Glenwood |e verfasserin |4 aut | |
| 700 | 1 | |a Wheatley-Price, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Shepherd, Frances A |e verfasserin |4 aut | |
| 700 | 1 | |a Florescu, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Cheema, Parneet |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Quincy S C |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Sang-We |e verfasserin |4 aut | |
| 700 | 1 | |a Morgensztern, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Melissa L |e verfasserin |4 aut | |
| 700 | 1 | |a Cousin, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Dong-Wan |e verfasserin |4 aut | |
| 700 | 1 | |a Moskovitz, Mor T |e verfasserin |4 aut | |
| 700 | 1 | |a Vicente, David |e verfasserin |4 aut | |
| 700 | 1 | |a Aronson, Boaz |e verfasserin |4 aut | |
| 700 | 1 | |a Hobson, Rosalind |e verfasserin |4 aut | |
| 700 | 1 | |a Ambrose, Helen J |e verfasserin |4 aut | |
| 700 | 1 | |a Khosla, Sajan |e verfasserin |4 aut | |
| 700 | 1 | |a Reddy, Avinash |e verfasserin |4 aut | |
| 700 | 1 | |a Russell, Deanna L |e verfasserin |4 aut | |
| 700 | 1 | |a Keddar, Mohamed Reda |e verfasserin |4 aut | |
| 700 | 1 | |a Conway, James P |e verfasserin |4 aut | |
| 700 | 1 | |a Barrett, J Carl |e verfasserin |4 aut | |
| 700 | 1 | |a Dean, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Rakesh |e verfasserin |4 aut | |
| 700 | 1 | |a Dressman, Marlene |e verfasserin |4 aut | |
| 700 | 1 | |a Jewsbury, Philip J |e verfasserin |4 aut | |
| 700 | 1 | |a Iyer, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Barry, Simon T |e verfasserin |4 aut | |
| 700 | 1 | |a Cosaert, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Heymach, John V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature medicine |d 1995 |g 30(2024), 3 vom: 13. März, Seite 716-729 |w (DE-627)NLM074659804 |x 1546-170X |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:3 |g day:13 |g month:03 |g pages:716-729 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41591-024-02808-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 3 |b 13 |c 03 |h 716-729 | ||